Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia Reviews Published on 2022-04-192022-10-05 Journal: Bone marrow transplantation [Category] 치료제, [키워드] accelerate administration antibody available data Bacterial infection benefit Blood Cell Characteristics chimeric antigen receptor clinical clinical trial CLL deficiency demonstrated disease dosage Efficacy Evidence Hematological malignancy heterogeneous HSCT HSCT recipient Hypogammaglobulinemia IgG immune Immunoglobulin immunoglobulin replacement therapy infection risk leukemia Meta-analysis monoclonal antibody Mortality MOST Multiple myeloma Other other disease Patient Prophylactic randomized trial regimen subsequent T-cell therapy utility [DOI] 10.1038/s41409-022-01680-z [Article Type] Reviews
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial Research Published on 2022-03-212022-10-05 Journal: Nature Medicine [Category] 바이오마커, 임상, [키워드] 95% CI 95% confidence interval Anti-CD19 autologous B-cell B-cell lymphoma Blood level CAR Central nervous system chimeric antigen receptor CNS Complete CRS Cytokine release syndrome Cytokines effective EFS evaluated event events Follow-up median median time multicenter neurologic nine occurred outcome Patient primary endpoint Primary outcome reached remained safety profile secondary single-arm survival T-cell therapy Treatment Trial [DOI] 10.1038/s41591-022-01731-4 [Article Type] Research
Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipientsCD19 표적 키메라 항원 수용체 T 세포 면역 요법 수용자에서 mRNA SARS-CoV-2 백신 3회 투여에 대한 면역 반응Observational Study Published on 2022-03-142022-09-11 Journal: Cancer cell [Category] MERS, SARS, 바이오마커, 임상, [키워드] chimeric antigen receptor dose Immunotherapy mRNA recipient SARS-CoV-2 vaccine T cell [DOI] 10.1016/j.ccell.2022.01.010 PMC 바로가기 [Article Type] Observational Study
Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patientsClinical Trial Published on 2022-03-082022-10-04 Journal: Blood advances [Category] SARS, 임상, [키워드] Allogeneic Analysis antibody Antibody concentrations Antigen autologous benefit binding antibody unit Cell cell transplantation Chemotherapy chimeric antigen receptor CLL Concentration COVID-19 vaccination disease HCT hematological hematology high risk High-dose identify IgG IgG4 Immunocompromised Immunoglobulin Immunosuppressant in healthy individuals leukemia lymphoma mRNA-1273 Multiple myeloma myeloid malignancies Netherland Obtaining Patient patients patients treated precluded predicted quantified recipient Registered response S1 IgG serum severe COVID-19 subunit T-cell therapy Treatment Trial vaccination Virus neutralization [DOI] 10.1182/bloodadvances.2021006917 PMC 바로가기 [Article Type] Clinical Trial
Vaccination for SARS-CoV-2 in Hematological Patients혈액학적 환자의 SARS-CoV-2 백신 접종Review Published on 2022-01-012022-09-11 Journal: Acta haematologica [Category] SARS, 임상, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adverse event adverse events Anti-CD20 antibodies antibody antigen receptor approach Better chimeric antigen receptor chronic lymphocytic leukemia chronic myeloid leukemia controlled trials coronavirus coronavirus disease Coronavirus disease 2019 correlation COVID-19 COVID-19 vaccine COVID-19 vaccines death demonstrated disease dose drugs effective Effectiveness evaluate excluded General population healthy subjects Hematological malignancies Hematological malignancy HM patient HM patients humoral Humoral response immune response Immunocompromised Immunocompromised patient Immunocompromised patients increased risk Infection kinase inhibitors leukemia Lymphocytic leukemia lymphoproliferative disorders mRNA vaccination mRNA vaccine Multiple myeloma Myeloma Non-Hodgkin Lymphoma non-randomized studies non-randomized study Patient patients patients with HM provided Randomized controlled trials reported respiratory response rate ruxolitinib Safe SARS-CoV-2 serology testing Seropositivity severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 severe disease T-cell T-cell Response T-cell responses therapy tyrosine tyrosine kinase inhibitors vaccination Vaccinations Vaccine venetoclax [DOI] 10.1159/000523753 PMC 바로가기 [Article Type] Review
mRNA Therapeutic Modalities Design, Formulation and Manufacturing under Pharma 4.0 PrinciplesReview Published on 2021-12-272022-10-28 Journal: Biomedicines [Category] COVID-19, [키워드] applicability approach benefit can be used CAR T-cell chimeric antigen receptor clinical entity concerning Continuous DNA Efficacy example Formulation Genome lab Lipid nanoparticle modality Modification mRNA mRNA vaccine mRNA vaccines mutability nanomedicine pandemic peptide peptides pharma industry 4.0 Precision principle protein replacement somatic cells stability Still storage T-cell targets the SARS-CoV-2 Therapeutics therapy translated Vaccine vector [DOI] 10.3390/biomedicines10010050 PMC 바로가기 [Article Type] Review
Glycoprotein Targeted CAR-NK Cells for the Treatment of SARS-CoV-2 InfectionImmunology Published on 2021-12-232022-11-01 Journal: Frontiers in Immunology [Category] COVID-19, SARS, [키워드] 293T cell ACE2 activated Anti-viral antiviral activity banana Banana Lectin BanLec bind binding CAR CAR-NK cells Cell cellular chimeric antigen receptor circulating COVID-19 Culture divorce effector cells Ex vivo expressed expressing Extracellular glycan glycobiology Immunotherapy infected cells Infection Inflammatory cytokine lectin lentiviral NK cell Patient Point mutation promote Protein pseudotyped receptor Receptor binding domain reduced S-protein SARS-CoV-2 SARS-CoV-2 envelope SARS-COV-2 infection SARS-CoV-2 virus secrete spike the SARS-CoV-2 therapeutic therapy viral clearance virus wild-type SARS-CoV-2 [DOI] 10.3389/fimmu.2021.763460 PMC 바로가기 [Article Type] Immunology
Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapyReview Article Published on 2021-10-202022-10-04 Journal: Signal Transduction and Targeted Therapy [Category] MERS, SARS, 바이오마커, 치료제, [키워드] adverse event Allogeneic Autoimmune diseases CAR-T Characteristics characterized chimeric antigen receptor circulating clinical feature clinical manifestations clinically COVID-19 CRS cytokine cytokine levels Cytokine release syndrome described disease disorder Efficacy elevated feature Fever Host human disease hyperinflammation Immunological disorders Immunotherapy incidence Infectious diseases Influenza Intervention life-threatening management mechanism organ dysfunction Pandemics pathway potential mechanism Regulation SARS-CoV signaling pathways Symptom syndrome systemic inflammatory therapy Toxicity [DOI] 10.1038/s41392-021-00764-4 PMC 바로가기 [Article Type] Review Article
Identification of Novel Modalities Through Bibliometric Analysis for Timely Development of Regulatory Guidance: A Case Study of T Cell ImmunityMedicine Published on 2021-10-112022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] Analysis antibody build carried catch CD28 cells characterized chimeric antigen receptor citation network clinical trial Cluster Clustering Cytokine release syndrome development domain domains Drug development evaluate Guidance help horizon scanning identification identify immune Immunity Immunotherapy IMPROVE information knowledge Medicine microbiota modality novel novel modality pathway Patient Perspective pharmacological public health Regulatory regulatory agency regulatory guidance Regulatory science regulatory T cells Research Result T cell T cell therapy T cells text mining Treatment Vaccines [DOI] 10.3389/fmed.2021.756870 PMC 바로가기 [Article Type] Medicine
The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple MyelomaReview article Published on 2021-10-012022-10-05 Journal: Transplantation and cellular therapy [Category] 비임상, [키워드] Annual CAR T-cell cellular therapy chimeric antigen receptor clinical Clinical trial design conducted Cytometry disease Endpoint Evolution flow cytometry hematology immune profiling Marrow meeting Minimal residual disease molecular Multiple Multiple myeloma Myeloma network Next-generation sequencing Profiling progression residual Society T-cell Testing Thursday Transplant workshop [DOI] 10.1016/j.jtct.2021.05.027 [Article Type] Review article